Ovarian cancer is one of the deadliest cancers affecting women. One reason it is so dangerous is that it is often discovered late, after the disease has already spread throughout the abdomen.
In many cases, symptoms remain vague in the early stages and may include bloating, stomach discomfort, feeling full quickly, or changes in appetite. Because these signs are easy to overlook, many patients are diagnosed only after the cancer has become advanced.
Doctors have long known that many women with advanced ovarian cancer develop a condition called ascites. Ascites happens when fluid builds up inside the abdomen, causing swelling, pain, pressure, breathing difficulty, and discomfort. In severe cases, doctors must drain the fluid to help patients feel better.
For years, ascites was mostly viewed as a side effect of advanced cancer rather than an important part of the disease itself. But now, researchers at Duke University School of Medicine have discovered that this fluid may actually help ovarian cancer survive and spread.
Their new study, published in Nature Communications, suggests that ascites acts almost like a protective shield for cancer cells. Even more surprising, the researchers found that an older cholesterol drug called bezafibrate may weaken this protection and make cancer cells more vulnerable.
The scientists stressed that the drug is not currently a treatment for ovarian cancer. However, the findings suggest researchers may one day improve cancer treatment by targeting the environment surrounding tumors rather than attacking the cancer cells alone.
The study was led by Dr. Jen-Tsan Chi, professor of molecular genetics and microbiology and co-leader of the Cancer Biology Program at the Duke Cancer Institute.
According to the researchers, ascites occurs in about 90% of patients with advanced ovarian cancer. Doctors already drain the fluid to reduce symptoms and improve quality of life, but the new study shows the fluid may play a much larger biological role than previously understood.
The team discovered that ascites protects cancer cells from a special type of cell death called ferroptosis. Ferroptosis happens when iron inside a cell reacts with fats, causing severe damage to the cell membrane. Scientists sometimes compare it to a type of cellular rusting.
Normally, many cancer cells that break away from tumors and float through the abdomen are vulnerable to ferroptosis. Without protection, these cells may die before they can spread and form new tumors elsewhere.
But the new research showed that ascites changes the situation completely.
The scientists tested ovarian cancer cells in the laboratory using real ascites fluid collected from patients. They exposed the cancer cells to conditions that normally trigger ferroptosis and observed what happened.
The results showed that the fluid protected cancer cells very effectively. Even small amounts of ascites were enough to shield the cells from destruction. Researchers found that just 2% exposure to the fluid could provide protection, even though in real patients the cancer cells are often fully surrounded by ascites.
The researchers discovered that the fluid changes how cancer cells handle fats and iron. These changes help block ferroptosis and allow the cancer cells to survive while traveling through the abdomen.
The team also noticed something very specific about the effect. Ascites did not protect the cancer cells from every type of cell death. It mainly blocked ferroptosis and did not significantly stop other well-known forms of cell death such as apoptosis or necrosis.
This finding helped the scientists narrow down what was causing the protective effect.
To investigate further, the researchers separated ascites into its main components, including proteins, lipids, and small molecules. They tested each part individually to see which one was responsible for protecting the cancer cells.
The answer turned out to be lipids, which are fatty molecules found inside the fluid. When researchers removed the lipids from ascites, the protective effect disappeared.
This discovery led the scientists to test whether drugs that affect fat processing might interfere with the cancer’s protection system.
One drug stood out: bezafibrate. Bezafibrate is an older cholesterol medication commonly used to lower triglyceride levels and change the way the body processes fats.
The researchers found that bezafibrate restored the cancer cells’ vulnerability to ferroptosis, but only when ascites was present. The drug itself did not directly kill the cancer cells or slow tumor growth in mice.
Instead, it seemed to work by changing the environment around the cancer cells and weakening the protection provided by the fluid.
The findings suggest that future cancer therapies may not only target tumors directly but may also target the surrounding environment that helps cancer survive.
Researchers believe this idea could extend beyond ovarian cancer. Other cancers, including pancreatic and colorectal cancers, may also spread within the abdominal cavity and interact with similar biological fluids.
In reviewing the study, the findings appear important because they shift attention toward the environment surrounding tumors rather than focusing only on the cancer cells themselves.
The experiments were carefully designed using patient-derived fluid and laboratory models, which strengthens the biological relevance of the results. However, the research is still at an early stage. The cholesterol drug did not directly stop tumor growth, and the study has not yet shown benefits in human patients.
Much larger clinical studies will be needed before any treatment recommendations can be made. Even so, the study opens an interesting new direction in cancer research by showing that changing the tumor environment may help weaken cancer defenses and improve future treatments.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
Source: Duke University School of Medicine.
